Table A2.
Author | Study Design | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Score | Maximum Score | Percentage | Low/Moderate/High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Akpede et al. [5] | cross-sectional | Y | Y | Y | Y | N | N | Y | Y | 12 | 16 | 75 | high | |||
Al Kaissi et al. [18] | case report | Y | Y | Y | Y | Y | Y | Y | N | 14 | 16 | 87.5 | high | |||
Al Kaissi et al. [19] | case series | N | Y | Y | UC | UC | Y | N | UC | Y | NA | 11 | 18 | 61.1 | moderate | |
Bar-On et al. [20] | case series | Y | UC | UC | Y | UC | Y | Y | Y | Y | NA | 15 | 18 | 83.3 | high | |
Bar-On et al. [14] | case series | Y | Y | Y | UC | UC | Y | Y | Y | Y | NA | 16 | 18 | 88.9 | high | |
Bharani et al. [21] | case report | Y | Y | Y | Y | N | NA | N | N | 12 | 14 | 85.7 | high | |||
Bhimma et al. [22] | case series | Y | Y | Y | UC | UC | Y | N | Y | Y | NA | 14 | 18 | 77.8 | high | |
Dudkiewicz et al. [23] | case report | N | Y | N | N | N | Y | Y | Y | 8 | 16 | 50 | moderate | |||
Eralp et al. [24] | case report | Y | N | Y | Y | Y | Y | N | Y | 12 | 16 | 75 | high | |||
Gigante et al. [25] | case series | Y | Y | UC | Y | UC | N | Y | Y | Y | NA | 14 | 18 | 77,8 | high | |
Kenis et al. [30] | case report | N | Y | Y | Y | Y | Y | N | Y | 12 | 16 | 75 | high | |||
Kim et al. [31] | case series | Y | Y | Y | N | UC | Y | Y | NA | N | Y | 13 | 18 | 72.2 | moderate | |
McKeand et al. [32] | case-control study | Y | UC | Y | Y | Y | N | N | Y | 11 | 16 | 68.75 | moderate | |||
Nayak et al. [34] | case report | N | Y | Y | Y | Y | Y | N | Y | 12 | 16 | 75 | high | |||
Nishimura et al. [35] | case series | Y | Y | Y | N | NA | N | N | Y | Y | NA | 10 | 16 | 62.5 | moderate | |
Oginni et al. [37] | prospective case series | Y | Y | Y | Y | Y | N | N | Y | Y | Y | 16 | 20 | 80 | high | |
Oni and Keswani [38] | case series | Y | UC | UC | UC | UC | N | Y | NA | Y | NA | 10 | 16 | 62.5 | moderate | |
Oni et al. [11] | case series | Y | UC | UC | Y | UC | N | Y | NA | N | NA | 9 | 16 | 56.3 | moderate | |
Oyemade [13] | case series | N | Y | Y | Y | UC | N | Y | Y | Y | NA | 13 | 18 | 72.2 | moderate | |
Oyemade [1] | case series | Y | Y | Y | Y | UC | N | Y | N | Y | NA | 13 | 18 | 72.2 | moderate | |
Paruk [39] | case report | Y | Y | Y | Y | Y | Y | Y | Y | 16 | 16 | 100 | high | |||
Pettifor et al. [41] | case series | N | Y | Y | UC | UC | Y | Y | Y | N | NA | 12 | 18 | 66.7 | moderate | |
Prakash [42] | prospective cohort | NA | NA | Y | NA | N | Y | Y | Y | Y | Y | Y | 14 | 16 | 87.5 | high |
Prentice et al. [43] | case-control study | UC | UC | Y | Y | Y | N | Y | Y | 12 | 16 | 75 | high | |||
Shehzad and Shaheen [44] | case report | Y | Y | Y | Y | Y | Y | N | N | 12 | 16 | 75 | high | |||
Simsek-Kiper et al. [45] | case series | N | Y | Y | UC | UC | Y | Y | NA | Y | NA | 12 | 16 | 75 | high | |
Smyth [4] | case report | Y | N | Y | Y | N | N | N | Y | 8 | 16 | 50 | moderate | |||
Solagberu [12] | prospective case series | Y | UC | Y | Y | UC | N | Y | N | Y | Y | 14 | 20 | 70 | moderate | |
Thacher et al. [47] | case report | Y | Y | Y | Y | Y | Y | N | Y | 14 | 16 | 87.5 | high | |||
Thacher et al. [9] | case-control study | Y | Y | Y | Y | Y | N | N | Y | 12 | 16 | 75 | high | |||
Thacher et al. [8] | cohort study | Y | Y | Y | N | N | N | Y | NA | NA | NA | Y | 10 | 16 | 62.5 | moderate |
Vatanavicharn et al. [48] | case report | Y | Y | Y | Y | NA | NA | NA | Y | 10 | 10 | 100 | high | |||
Weiner et al. [49] | case series | N | Y | UC | UC | UC | Y | Y | NA | Y | NA | 11 | 16 | 68.8 | moderate | |
Yilmaz et al. [50] | cohort study | Y | Y | Y | N | N | Y | Y | Y | Y | UC | Y | 15 | 22 | 68.2 | moderate |